Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive ...

At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...